KRAS
GTPase KRas
As of the edition of 20 October 2026, KRAS (GTPase KRas, UniProt P01116) has 42 drugs tested at it and 35 companies on the list, 3 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P01116
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 556
- Disease areas
- Cancer; Lungs and airways; Digestive system; Hormones; Urinary and reproductive; Pregnancy and women's health; Nervous system; Heart and blood vessels
- Registered trials of its drugs
- 237
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 30 |
| Went quiet | 3 |
| Stopped | 3 |
| Status not established | 4 |
| Total | 42 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sotorasib | Marketed | Phase 4 | Ends 2040 |
| Adagrasib | Marketed | Phase 3 | Ends 2041 |
| Olomorasib | Active | Phase 3 | none listed |
| Divarasib | Active | Phase 3 | none listed |
| Garsorasib | Active | Phase 3 | none listed |
| Glecirasib | Active | Phase 3 | none listed |
| HRS-4642 | Active | Phase 2 | none listed |
| Opnurasib | Active | Phase 3 | none listed |
| BI 1701963 | Active | Phase 1 | none listed |
| GFH375 | Active | Phase 3 | none listed |
| IBI351 | Active | Phase 1 | none listed |
| Setidegrasib | Active | Phase 3 | none listed |
12 of 42 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 2 |
| Engaged | 28 |
| Undetermined | 2 |
| Total on the list | 35 |
| Company | Route |
|---|---|
| Amgen | Route B |
| AstraZeneca | Route A |
| BeiGene | Route A |
The other 32 companies at KRAS
In the product35 companies in all; 32 are not named here, and no score is.
See the 35 companies at KRAS, ranked, with the facts behind eachRequest access. Nothing is shown until you do.